Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Sezgi Kipcak"'
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 9, p 7817 (2023)
Barrett’s esophagus (BE) is a disease entity that is a sequela of chronic gastroesophageal reflux disease that may result in esophageal adenocarcinoma (EAC) due to columnar epithelial dysplasia. The histological degree of dysplasia is the sole biom
Externí odkaz:
https://doaj.org/article/44b8ff45d0814fa391be9e77e557abd0
Autor:
Leila Sabour Takanlou, Buket Özel, Cumhur Gündüz, Maryam Sabour Takanlou, Cigir Biray Avci, Sezgi Kipcak, Nur Selvi Günel
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 21:1724-1731
Background: Chronic Myeloid Leukemia (CML) is characterized by a reciprocal translocation t(9;22) and forms BCR/ABL1 fusion gene called the Philadelphia chromosome. The therapeutic targets for CML patients mediated with BCR/ABL1 oncogenic are tyrosin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2839948407b8004cbebae2fb16c3898c
https://doi.org/10.2174/1871520620666201106085929
https://doi.org/10.2174/1871520620666201106085929
Autor:
Buket Ozel, Sezgi Kipcak, Cigir Biray Avci, Maryam Sabour Takanlou, Leila Sabour Takanlou, Burcin Tezcanli Kaymaz, Ilknur Karatekin, Cumhur Gunduz, Nur Selvi Gunel
Publikováno v:
Medical oncology (Northwood, London, England). 39(9)
Chronic myeloid leukemia (CML) is a myeloproliferative disease that mediated by BCR/ABL oncogenic signaling. CML can be targeted with the imatinib, dasatinib, and nilotinib TKI inhibitors, the latter two of them have been approved for imatinib-resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42cadf5d098ae65edb94485230377465
https://pubmed.ncbi.nlm.nih.gov/35716222
https://pubmed.ncbi.nlm.nih.gov/35716222
Goal: The aim of this study was to investigate the pepsin values and pH results of gastric juice among the subtypes of gastroesophageal reflux disease (GERD) and functional heartburn. Background: The major destructive agents of GERD on the esophageal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28e20bc15982088f9f057eba8f27d9b7
https://hdl.handle.net/11454/77396
https://hdl.handle.net/11454/77396
Autor:
Cigir Biray Avci, Fatma Sogutlu, Cagla Kayabasi, Sunde Yilmaz Susluer, Besra Ozmen Yelken, Sezgi Kipcak, Aycan Asik, Roya Gasimli, Cumhur Gündüz
Background: Dysregulation of the cell cycle is one of the main causes of melanomagenesis. Genomewide studies showed that the expression of Aurora -A and -B significantly has been upregulated in melanoma. However, there is no FDA approved drug targeti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b5b8776390dd1331d7a8cec3d556cc0
https://hdl.handle.net/11454/78173
https://hdl.handle.net/11454/78173
Autor:
Sezgi Kipcak, Nur Selvi Günel
Publikováno v:
Volume: 11, Issue: 3 251-260
Pamukkale Tıp Dergisi
Pamukkale Tıp Dergisi
Amaç:Akut miyeloid lösemi (AML), hematopoetik öncül hücrelerin heterojen klonal bir hastalığıdır. Akut promiyelositer lösemi (APL), bir AML alt tipidir ve morfolojik olarak anormal promiyelositler ile karakterize edilir. APL’de görülen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97aac4e1e08577cd394259b41ca8a34d
https://hdl.handle.net/11454/66285
https://hdl.handle.net/11454/66285
Publikováno v:
Clinical Gastroenterology and Hepatology. 15:319-320
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d75de58e91012e49d50284a07832b365
https://doi.org/10.1016/j.cgh.2016.09.136
https://doi.org/10.1016/j.cgh.2016.09.136
Autor:
Burçin Tezcanlı Kaymaz, Sezgi Kipcak, Nur Selvi Günel, Çağdaş Aktan, Melis Kartal Yandim, Buket Kosova Can, Aysun Adan Gökbulut, Buket Özel, Yusuf Baran, Metin Ceyhan, Vildan Bozok Çetintaş
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 36(10)
BCR-ABL oncoprotein stimulates cell proliferation and inhibits apoptosis in chronic myeloid leukemia (CML). For cure, imatinib is a widely used tyrosine kinase inhibitor, but developing chemotherapeutic resistance has to be overcome. In this study, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19f6dd401874a03e69a0917743ad15f5
https://pubmed.ncbi.nlm.nih.gov/25953263
https://pubmed.ncbi.nlm.nih.gov/25953263